中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (34): 5110-5115.doi: 10.3969/j.issn.2095-4344.2016.34.015

• 药物控释材料 drug delivery materials • 上一篇    下一篇

 雷帕霉素和紫杉醇药物洗脱支架治疗冠状动脉开口病变:1年随访评价有效和安全性

陈小龙   

  1. 南阳医学高等专科学校第一附属医院心血管内科,河南省南阳市 473000
  • 收稿日期:2016-05-21 出版日期:2016-08-19 发布日期:2016-08-19
  • 作者简介:陈小龙,男,1977年生,河南省南阳市人,主治医师,主要从事心血管内科研究。

Rapamycin-eluting stent versus paclitaxel-eluting stent for coronary ostial lesions: effective and safety evaluation after 1-year follow-up

Chen Xiao-long   

  1. Department of Cardiology, First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, Henan Province, China
  • Received:2016-05-21 Online:2016-08-19 Published:2016-08-19
  • About author:Chen Xiao-long, Attending physician, Department of Cardiology, First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, Henan Province, China

摘要:

文章快速阅读:

 

文题释义:
药物洗脱支架
:也称之为药物释放支架,通过包被于金属支架表面的聚合物携带药物,当支架置入血管内病变部位后,药物自聚合物涂层中通过洗脱方式有控制地释放至血管壁组织而发挥生物学效应。目前,临床使用较为广泛的洗脱支架主要有2种:紫杉醇洗脱支架和雷帕霉素洗脱支架。
紫杉醇:属于衍生的二萜类化合物,它可与一些β-微管蛋白发生特异性结合,对α、β微管蛋白的聚合起有效的促进作用,进而对细胞分裂、增殖等产生有效抑制作用。
雷帕霉素:是医学临床上一种常见的强效免疫抑制剂,本质上是一种新型大环内酯的抗排斥药物,临床被用来治疗各种免疫性疾病,对各种疾病的排斥反应有很好的治疗效果。


背景:雷帕霉素和紫杉醇药物洗脱支架被广泛应用于冠状动脉开口病变治疗(左主干开口和右冠开口病变),但有关两者治疗有效性和安全性的对比研究较少。
目的:对比雷帕霉素和紫杉醇药物洗脱支架置入治疗冠状动脉开口病变的有效性和安全性。
方法:纳入135例冠状动脉开口病变患者,按随机数表法将患者分为2组,其中62例在冠状动脉开口处置入紫杉醇洗脱支架,73例在冠状动脉开口处置入雷帕霉素洗脱支架。置入后随访12个月,对比两组心脏不良事件发生率、血栓形成、靶病变血运重建及支架再狭窄情况。
结果与结论:①两组均未发生支架脱落或移位,未发生与支架材料相关的不良反应;②雷帕霉素洗脱支架组与紫杉醇洗脱支架组心脏不良事件发生率(8.5%、6.8%)、血栓形成发生率(3.9%、4.1%)、靶病变血运重建率(4.1%、6.4%)、支架内再狭窄率(7.5%、9.2%)比较差异均无显著性意义;③结果表明:雷帕霉素与紫杉醇药物洗脱支架置入治疗冠状动脉开口病变的有效性和安全性相当。

ORCID: 0000-0003-1784-5141(陈小龙)

关键词: 生物材料, 材料相容性, 雷帕霉素洗脱支架, 紫杉醇洗脱支架, 冠状动脉开口病变, 心血管事件, 有效性, 安全性

Abstract:

BACKGROUND: Rapamycin and paclitaxel eluting stents have been widely used in the treatment of coronary ostial lesions (left main coronary artery and right coronary artery ostial lesions). However, the comparative research on the effectiveness and safety of the two stents for coronary ostial lesions is relatively rare.
OBJECTIVE: To explore the efficacy and safety of the rapamycin-eluting stent versus paclitaxel-eluting stent in the treatment of coronary ostial lesions.
METHODS: 135 patients with coronary ostial lesions were selected and were allotted into two groups by random number table, 73 cases treated with rapamycin-eluting stent and the remaining 62 cases treated with paclitaxel-eluting stent. After 12-month follow-up, the incidence of adverse cardiac events, thrombosis, target lesion revascularization and stent-restenosis were compared between two groups.
RESULTS AND CONCLUSION: Neither did stent drop off or displace, nor did other adverse reactions related to the stent occurr in both two groups. The incidence of cardiac adverse events in the rapamycin group and paclitaxel group was 8.5% and 6.8%; the rate of thrombosis was 3.9% and 4.1%; the rate of the target lesion revascularization was 4.1% and 6.4%; the rate of stent-restenosis was 7.5% and 9.2%, respectively. All above indicators showed no significant differences between two groups. In conclusion, the efficacy and safety of the rapamycin-eluting stent for coronary ostial lesions are equivalent to those of the paclitaxel-eluting stent.

 

 

中国组织工程研究杂志出版内容重点:生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程

中图分类号: